Sign Up

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23.

Global net revenues from the immunology portfolio were $7.63 billion, up 9.5% (+9.2% on an operational basis), including-Skyrizi sales increased 62.2% (+61.8%) to $4.42 billion; Rinvoq sales reached $2.03 billion, an increase of 41.8% (+41.2%); and Humira sales fell 58.1% (-58.2%) to $1.18 billion.

Oncology portfolio generated sales of $1.68 billion, up 2.6% (+2.4%), including- Imbruvica’s net revenues were $754 million, down 9.5%; Venclexta’s revenues were $691 million, up 8.5% (+8.3%); and Elahere’s revenues were $159 million.

Also Read: AbbVie’s Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial

Neuroscience portfolio sales were $2.68 billion, up 24.2% (+24%), including-Vraylar net revenues were $900 million, up 16.3%; and Botox Therapeutic’s net revenues were $928 million, up 14.1% (+14.2%).

Outlook

AbbVie raises its fiscal 2025 adjusted earnings from $11.67-$11.87 per share to $11.88-$12.08 compared to the analysts’ estimate of $12.24.

This includes an unfavorable impact of 55 cents per share related to acquired IPR&D and milestones expense incurred year-to-date ...